Helen E. Heslop
Impact in
- Oncology top 0.01%
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- Immunology top 0.05%
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
Papers in
- Oncology 302
- CAR-T cell therapy research 184
- Viral-associated cancers and disorders 92
- Immunology 177
- Immune Cell Function and Interaction 102
- Immunotherapy and Immune Responses 52
- Co-authors
- Cliona M. Rooney (218 shared papers)Malcolm K. Brenner (237 shared papers)Gianpietro Dotti (73 shared papers)Barbara Savoldo (71 shared papers)Catherine M. Bollard (100 shared papers)Adrian P. Gee (88 shared papers)Robert A. Krance (97 shared papers)Hao Liu (33 shared papers)
- Journals
- Blood (103 papers)Biology of Blood and Marrow Transplantation (57 papers)Molecular Therapy (22 papers)Cytotherapy (21 papers)British Journal of Haematology (12 papers)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
Helen E. Heslop
414 papers receiving 27.7k citations
Helen E. Heslop's Hit Papers
Peers
Comparison fields: 5 of 149
- Oncology 21.3k
- Immunology 10.8k
- Hematology 3.1k
- Genetics 7.7k
- Pathology and Forensic Medicine 3.1k
Countries citing papers authored by Helen E. Heslop
This map shows the geographic impact of Helen E. Heslop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen E. Heslop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen E. Heslop more than expected).
Fields of papers citing papers by Helen E. Heslop
This network shows the impact of papers produced by Helen E. Heslop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen E. Heslop. The network helps show where Helen E. Heslop may publish in the future.
Co-authors
The 25 scholars most cited alongside Helen E. Heslop, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 426 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy Hit paper breakdown → | 2011 | 1159 |
| 2 | Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma Hit paper breakdown → | 2008 | 919 |
| 3 | Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma Hit paper breakdown → | 2011 | 882 |
| 4 | Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipients Hit paper breakdown → | 1998 | 859 |
| 5 | CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients Hit paper breakdown → | 2011 | 794 |
| 6 | Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes Hit paper breakdown → | 1996 | 668 |
| 7 | Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients Hit paper breakdown → | 2009 | 589 |
| 8 | Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15 Hit paper breakdown → | 2014 | 569 |
| 9 | An inducible caspase 9 safety switch for T-cell therapy Hit paper breakdown → | 2005 | 560 |
| 10 | 2010 | 455 | |
| 11 | 2009 | 449 | |
| 12 | 2006 | 432 | |
| 13 | 2005 | 398 | |
| 14 | 2013 | 392 | |
| 15 | CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma Hit paper breakdown → | 2017 | 391 |
| 16 | Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins Hit paper breakdown → | 2013 | 384 |
| 17 | 2013 | 378 | |
| 18 | 2004 | 349 | |
| 19 | 1993 | 338 | |
| 20 | 2010 | 319 |
About Helen E. Heslop
Helen E. Heslop is a scholar working on Oncology, Immunology, Epidemiology, Genetics and Hematology, having authored 426 papers that have together received 28.1k indexed citations. Recurring topics across this work include CAR-T cell therapy research (184 papers), Cytomegalovirus and herpesvirus research (116 papers), Virus-based gene therapy research (112 papers), Immune Cell Function and Interaction (102 papers), Viral-associated cancers and disorders (92 papers), Hematopoietic Stem Cell Transplantation (71 papers), Lymphoma Diagnosis and Treatment (58 papers) and Immunotherapy and Immune Responses (52 papers). The work is most often cited by research in Oncology (21.3k citations), Immunology (10.8k citations), Hematology (3.1k citations), Genetics (7.7k citations) and Pathology and Forensic Medicine (3.1k citations). Helen E. Heslop has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Cliona M. Rooney, Malcolm K. Brenner, Gianpietro Dotti, Barbara Savoldo, Catherine M. Bollard, Adrian P. Gee, Robert A. Krance, Hao Liu, Stephen Gottschalk and Ann M. Leen. Their work appears in journals such as Blood, Biology of Blood and Marrow Transplantation, Molecular Therapy, Cytotherapy and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.